Optimal Heart Failure Medical Therapy and Mortality in Survivors of Cardiogenic Shock: Insights From the FRENSHOCK Registry
Authors:
- Kensuke MatsushitaKMKensuke Matsushita
- Clément DelmasCDClément Delmas
- Benjamin MarchandotBMBenjamin Marchandot
- François RoubilleFRFrançois Roubille
- Guillaume LeurentGLGuillaume Leurent
- Bruno LevyBLBruno Levy
- Meyer ElbazMEMeyer Elbaz
- Pascal LimPLPascal Lim
- Francis SchneiderFSFrancis Schneider
- Hadi KhachabHKHadi Khachab
Open Access
- 5 March 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (5) , e030975
Abstract
Background: The effects of pharmacological therapy on cardiogenic shock (CS) survivors have not been extensively studied. Thus, this study investigated the association between guideline‐directed heart failure (HF) medical therapy (GDMT) and one‐year survival rate in patients who are post‐CS. Methods and Results: FRENSHOCK (French Observatory on the Management of Cardiogenic Shock in 2016) registry was a prospective multicenter observational survey, conducted in metropolitan French intensive care units and intensive cardiac care units. Of 772 patients, 535 patients were enrolled in the present analysis following the exclusion of 217 in‐hospital deaths and 20 patients with missing medical records. Patients with triple GDMT (beta‐blockers, renin‐angiotensin system inhibitors, and mineralocorticoid receptor antagonists) at discharge (n=112) were likely to have lower left ventricular ejection fraction on admission and at discharge compared with those without triple GDMT (n=423) (22% versus 28%, P P P =0.007). Similarly, 2:1 propensity score matching and inverse probability treatment weighting based on the propensity score demonstrated a lower incidence of one‐year mortality in the triple GDMT group. As the number of HF drugs increased, a stepwise decrease in mortality was observed (log rank; P <0.001). Conclusions: In survivors of CS, the one‐year mortality rate was significantly lower in those with triple GDMT. Therefore, this study suggests that intensive HF therapy should be considered in patients following CS.Keywords
This publication has 39 references indexed in Scilit:
- Guideline‐directed medical therapy in patients undergoing transcatheter edge‐to‐edge repair for secondary mitral regurgitationEuropean Journal of Heart Failure, 2022
- Baseline Characteristics, Management, and Predictors of Early Mortality in Cardiogenic Shock: Insights from the FRENSHOCK RegistryESC Heart Failure, 2021
- Comparison of In-Hospital Outcomes of Patients with vs. Without Ischaemic Cardiomyopathy Undergoing Veno-Arterial-Extracorporeal Membrane OxygenationESC Heart Failure, 2021
- Epidemiology, Pathophysiology and Contemporary Management of Cardiogenic Shock – A Position Statement from the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2020
- Cardiogenic shock during heart failure hospitalizations: Age-, sex-, and race-stratified trends in incidence and outcomesAmerican Heart Journal, 2019
- Design and preliminary results of FRENSHOCK 2016: A prospective nationwide multicentre registry on cardiogenic shockArchives of Cardiovascular Diseases, 2019
- Clinical Phenotypes and Outcome of Patients Hospitalized for Acute Heart Failure: The ESC Heart Failure Long-Term RegistryEuropean Journal of Heart Failure, 2017
- Clinical Picture and Risk Prediction of Short-Term Mortality in Cardiogenic ShockEuropean Journal of Heart Failure, 2015
- Impact of Worsening Renal Function Related to Medication in Heart FailureEuropean Journal of Heart Failure, 2014
- Influence of Systolic Blood Pressure on Clinical Outcomes in Elderly Heart Failure Patients Treated with Nebivolol: Data from the SENIORS TrialEuropean Journal of Heart Failure, 2014